Ascendia Pharmaceuticals is a specialty pharmaceutical CDMO that provides custom sterile- and non-sterile-enabling formulations and manufacturing, using all GRAS (Generally Regarded As Safe) along with analytical methods for new chemical entities, complex dosage forms, and 505(B)(2) product development, as well as OTCs, nutraceuticals, and animal health.
Ascendia makes the Insoluble Soluble by delivering sophisticated formulations to enhance bioavailability and solubility using its four proprietary nanotechnologies – NanoSol®, EmulSol®, AmorSol®, and LipidSol®. The company built its foundation of success on its customer-centric culture that boasts its BEST philosophy (Brilliant technology, Excellent service, Superior quality, and Trust).
Our rapid advancement of compounds from discovery to clinical testing provides clinical trial formulations suitable for initial animal studies and toxicology studies using our nano-emulsion, amorphous solid dispersion, controlled release and nano-particle engineering approaches.
By working with Ascendia, our clients can quickly determine the feasibility of multiple technical approaches in parallel, thus improving the probability of formulation success and reducing the time required to make critical early-stage formulation decisions. Many clients have anointed Ascendia as a “Partner of Choice”.
Following formulation selection and optimization, Ascendia can expediently transition a development program to cGMP clinical material manufacturing. Ascendia’s sterile and non-sterile manufacturing capabilities include orally administered dosage forms and injectable pre-filled syringe, vial and cartridge dosage forms. Ascendia offers its manufacturing services to biotech and pharmaceutical companies who seek a CDMO partner for their formulations as it transfers from a preclinical phase to early clinical development, scale-up to late-stage clinical trials and robust commercial supply.